Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2072-2078

  Miyahara, K ^a,h   Nouso, K ^a   Morimoto, Y ^a   Takeuchi, Y ^a   Hagihara, H ^a   Kuwaki, K ^a   Onishi, H ^a   Ikeda, F ^a   Miyake, Y ^a   Nakamura, S ^a   Shiraha, H ^a   Takaki, A ^a   Honda, M ^b   Kaneko, S ^b   Sato, T ^c   Sato, S ^c   Obi, S ^c   Iwadou, S ^d   Kobayashi, Y ^d   Takaguchi, K ^e   Kariyama, K ^f   Takuma, Y ^g   Takabatake, H ^g   Yamamoto, K ^a   Yamamoto, Kazuhide ^h   Morimoro, Yuki ^h   Takuma, Yoshitaka ^g   Takabatake, Hiroyuki ⁱ   Fujioka, Shin Ichi ⁱ   Osawa, Toshiya ^f   Kariyama, Kazuya ^f   Toshimori, Junichi ^f   Kobashi, Haruhiko ^j   Miyatake, Hirokazu ^j   Uematsu, Shuji ^j   Okamoto, Ryoichi ^d   Araki, Yasuyuki ^d   Tatsukawa, Masafumi ^k   Yabushita, Kazuhisa ^k   Shimoe, Toshinari ^l   Sakaguchi, Kohsaku ^l   Sakata, Tatsuro ^m   Kaneyoshi, Toshihiko ^m   Miyashita, Manabi ⁿ   Makino, Yasuhiro ⁿ   Moriya, Akio ⁿ   Ando, Masaharu ^e   Baba, Nobuyuki ^e   Seno, Tomonori ^e   Nagano, Takuya ^o   Matsumoto, Eiji ^o   Takayama, Hiroki ^p   more..

^a OKAYAMA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c Kyoundo Hospital   (Japan)

^d HIROSHIMA CITY HOSPITAL   (Japan)

^e KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f Okayama Citizens Hospital   (Japan)

^g KURASHIKI CENTRAL HOSPITAL   (Japan)

^h OKAYAMA UNIVERSITY   (Japan)

ⁱ OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^j Japanese Red Cross Okayama Hospital   (Japan)

^k Fukuyama City Hospital   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^m IWAKUNI NATIONAL HOSPITAL   (Japan)

ⁿ Japan   (Japan)

^o Sumitomo Besshi Hospital   (Japan)

^p Tsuyama Central Hospital   (Japan)

more..

Author keywords

angiogenesis; angiopoietin 2; cytokine; hepatocellular carcinoma; sorafenib

Indexed keywords

ANGIOPOIETIN 2; CYTOKINE; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84885929021     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.554     Document Type: Article

References (27)

1. Abramsson A, Lindblom P, Betsholtz C (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112: 1142-1151.
2. Bruix J, Sherman M. American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: An update. Hepatology 53: 1020-1022.
3. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
4. Cao G, Fehrenbach ML, Williams JT, Finklestein JM, Zhu JX, Delisser HM (2009) Angiogenesis in platelet endothelial cell adhesion molecule-1-null mice. Am J Pathol 175: 903-915.
5. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
8. Glienke J, Schmitt AO, Pilarsky C, Hinzmann B, Weiss B, Rosenthal A, Thierauch KH (2000) Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem 267: 2820-2830.
9. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
10. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
11. Kozian DH, Ziche M, Augustin HG (1997) The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest 76: 267-276.
12. Kudo M (2011) Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy. Oncology 81(Suppl 1): 1-10.
13. Laurén J, Gunji Y, Alitalo K (1998) Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol 153: 1333-1339.
14. LeCouter J, Lin R, Tejada M, Frantz G, Peale F, Hillan KJ, Ferrara N (2003) The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA 100: 2685-2690.
15. Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235.
16. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
17. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Panel of Experts in HCC-Design Clinical Trials (2008b) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
18. Llovet JM, Pen?a CE, Lathia CD, Shan M, Meinhardt G, Bruix J. SHARP Investigators Study Group (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18: 2290-2300.
19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Ha?ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. SHARP Investigators Study Group (2008a) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
20. Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K (2011) Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 26: 1604-1611.
21. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N (2009) G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 106: 6742-6747.
22. Sierra-Honigmann MR, Nath AK, Murakami C, Garc?́a-Carden?a G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR (1998) Biological action of leptin as an angiogenic factor. Science 281: 1683-1686.
23. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR (1999) Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103: 341-345.
24. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalling. Mol Cancer Ther 7: 3129-3140.
25. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
26. Zarnegar R (1995) Regulation of HGF and HGFR gene expression. EXS 74: 33-49.
27. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 27: 3027-3035.